International Journal of Drug Policy
Volume 20, Issue 6 , Pages 458-466 , November 2009

The adverse health effects of cannabis use: What are they, and what are their implications for policy?

Paper presented to the International Society for the Study of Drug Policy, Lisbon, Portugal, April 2008

  • Wayne Hall

      Affiliations

    • Corresponding Author InformationTel.: +61 7 336 55418; fax: +61 7 336 55442.

Received 24 June 2008 ,Revised 12 January 2009 ,Accepted 26 February 2009.

References 

  1. Aceto M, Scates S, lowe A, Martin B. Dependence studies on delta-9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics. 1996;278:1290–1295
  2. Adams IB, Martin BR. Cannabis: Pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–1614
  3. AIHW . Closed treatment episodes: Client profile by principal drug of concern, AODTS-NMDS 2005-05. Canberra: Australian Institute of Health and Welfare; 2006;
  4. Ajdacic-Gross V, Lauber C, Warnke I, Haker H, Murray RM, Rossler W. Changing incidence of psychotic disorders among the young in Zurich. Schizophrenia Research. 2007;95(1–3):9–18
  5. Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: A case–control study. European Respiratory Journal. 2008;31(2):280–286
  6. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax. 2007;62(12):1058–1063
  7. Andreasson S, Engstrom A, Allebeck P, Rydberg U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483–1486
  8. Anthony JC. The epidemiology of cannabis dependence. In:  Roffman RA,  Stephens RS editor. Cannabis dependence: Its nature, consequences and treatment. Cambridge, UK: Cambridge University Press; 2006;p. 58–105
  9. Anthony JC, Helzer JE. Syndromes of drug abuse and dependence. In:  Robins LN,  Regier DA editor. Psychiatric disorders in America: The epidemiologic catchment area. New York: Free Press; 1991;p. 116–154
  10. Anthony JC, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology. 1994;2(3):244–268
  11. Aronow W, Cassidy J. Effect of marihuana and placebo marihuana smoking on angina pectoris. New England Journal of Medicine. 1974;291:65–67
  12. Aronow W, Cassidy J. Effect of smoking marijuana and of a high nicotine cigarette on angina pectoris. Clinical Pharmacology and Therapeutics. 1975;17:549–554
  13. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ. 2002;325(7374):1212–1213
  14. Asbridge M, Poulin C, Donato A. Motor vehicle collision risk and driving under the influence of cannabis: Evidence from adolescents in Atlantic Canada. Accident Analysis and Prevention. 2005;37(6):1025–1034
  15. Bates MN, Blakely TA. Role of cannabis in motor vehicle crashes. Epidemiologic Reviews. 1999;21:222–232
  16. Bilder R, Volavka J, Lachman H, Grace A. The catechol-O-methyltransferase (COMT) polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943–1961
  17. In:  Bonnie RJ,  Stratton K,  Wallace AL editor. Ending the tobacco problem: A blue-print for the nation. Washington, DC: The National Academies Press; 2007;
  18. Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, et al. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychological Medicine. 2006;36(10):1441–1446
  19. Brereton D. The history and politics of prohibition. In:  Stokes G,  Chalk P,  Gillen K editor. Drugs and democracy: In search of new directions. Melbourne: Melbourne University Press; 2000;p. 85–97
  20. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Current Opinion in Psychiatry. 2006;19(3):233–238
  21. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry. 2004;161(11):1967–1977
  22. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94(9):1311–1322
  23. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioural sensitization after repeated exposure to [Delta]9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology. 2001;158(3):259–266
  24. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biological Psychiatry. 2005;57(10):1117–1127
  25. Chait LD, Pierri J. Effects of smoked marijuana on human performance: A critical review. In:  Murphy LB,  Bartke A editor. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press; 1992;p. 387–424
  26. Chesher G, Hall WD. Effects of cannabis on the cardiovascular and gastrointestinal systems. In:  Kalant H,  Corrigall W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;p. 435–458
  27. Coffey C, Carlin JB, Lynskey MT, Li N, Patton GC. Adolescent precursors of cannabis dependence: Findings from the Victorian Adolescent Health Cohort Study. British Journal of Psychiatry. 2003;182:330–336
  28. Cohen S. The 94-day cannabis study. Annals of the New York Academy of Sciences. 1976;282:110–211
  29. Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Advances in Alcohol and Substance Abuse. 1990;9(1–2):129–147
  30. Cook SA, Lowe JA, Martin BR. CB1 receptor antagonist precipitates withdrawal in mice exposed to delta9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. 1998;285(3):1150–1156
  31. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. Journal of Substance Abuse Treatment. 2001;20(1):45–52
  32. D'Souza DC. Cannabinoids and psychosis. International Review of Neurobiology. 2007;78:289–326
  33. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry. 2005;57(6):594–608
  34. D'Souza DC, Cho HS, Perry E, Krystal JH. Cannabinoid ‘model’ psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. In:  Castle DJ,  Murray RM editor. Marijuana and madness. Cambridge, UK: Cambridge University Press; 2004;p. 142–165
  35. Degenhardt L, Hall WD. The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-being. Psychological Medicine. 2001;31(4):659–668
  36. Degenhardt L, Hall WD, Lynskey MT. Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence. 2003;71(1):37–48
  37. Dennis M, Babor TF, Roebuck MC, Donaldson J. Changing the focus: The case for recognizing and treating cannabis use disorders. Addiction. 2002;97:4–15
  38. Donovan JE, Jessor R. Problem drinking and the dimension of involvement with drugs: A Guttman scalogram analysis of adolescent drug use. American Journal of Public Health. 1983;73(5):543–552
  39. Donovan JE, Jessor R. Structure of problem behavior in adolescence and young adulthood. Journal of Consulting and Clinical Psychology. 1985;53(6):890–904
  40. Duncan SC, Duncan TE, Biglan A, Ary D. Contributions of the social context to the development of adolescent substance use: A multivariate latent growth modeling approach. Drug and Alcohol Dependence. 1998;50(1):57–71
  41. Dutch National Alcohol and Drug Information System . Treatment demand of cannabis clients in outpatient addiction care in the Netherlands (1994–2001). LADIS Bulletin. 2004;(April)
  42. Ellickson P, Bui K, Bell R, McGuigan KA. Does early drug use increase the risk of dropping out of high school?. Journal of Drug Issues. 1998;28(2):357–380
  43. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta(9)-THC and other cannabinoids in confiscated marijuana from 1980–1997. Journal of Forensic Sciences. 2000;45(1):24–30
  44. EMCDDA (2003). Annual report 2003: The state of the drugs problem in the European Union and Norway. Luxembourg: Office for Official Publications of the European Communities.
  45. EMCDDA. (2004). EMCDDA Insights: An overview of cannabis potency in Europe. Luxembourg: Office for Official Publications of the European Communities.
  46. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: Testing the cannabis gateway hypothesis. Addiction. 2006;101(4):556–569
  47. Fergusson DM, Horwood JL, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychological Medicine. 2003;33:15–21
  48. Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction. 1997;92(3):279–296
  49. Fergusson DM, Horwood LJ. Prospective childhood predictors of deviant peer affiliations in adolescence. Journal of Child Psychology and Psychiatry and Allied Disciplines. 1999;40(4):581–592
  50. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use?. Addiction. 2000;95(4):505–520
  51. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005;100(3):354–366
  52. Fergusson DM, Horword LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction. 2002;97:1123–1135
  53. Fergusson DM, Lynskey MT, Horwood LJ. The short-term consequences of early onset cannabis use. Journal of Abnormal Child Psychology. 1996;24(4):499–512
  54. Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004;99:686–696
  55. Gardner E. Cannabinoid interaction with brain reward systems. In:  Nahas G,  Sutin K,  Harvey D,  Agurell S editor. Marihuana and medicine. Towa, NJ: Humana Press; 1999;p. 187–205
  56. Gerberich SG, Sidney S, Braun BL, Tekawa IS, Tolan KK, Quesenberry CP. Marijuana use and injury events resulting in hospitalization. Annals of Epidemiology. 2003;13(4):230–237
  57. Gottschalk L, Aronow W, Prakash R. Effect of marijuana and placebo-marijuana smoking on psychological state and on psychophysiological and cardiovascular functioning in angina patients. Biological Psychiatry. 1977;12(2):255–266
  58. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Kruger HP, Longo M, et al. Developing limits for driving under cannabis. Addiction. 2007;102(12):1910–1917
  59. Hall WD. The public health significance of cannabis use in Australia. Australian Journal of Public Health. 1995;19(3):235–242
  60. Hall WD. The recent Australian debate about the prohibition on cannabis use. Addiction. 1997;1109–1115
  61. Hall WD. Assessing the health and psychological effects of cannabis use. In:  Kalant H,  Corrigall W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;p. 1–17
  62. Hall WD. Cannabis use and the mental health of young people. Australian and New Zealand Journal of Psychiatry. 2006;40(2):105–113
  63. Hall WD. A cautious case for cannabis depenalization. In:  Earleywine M editors. Pot politics: Marijuana and the costs of prohibition. Oxford University Press; 2007;p. 91–112
  64. Hall WD, Degenhardt L, Lynskey MT. The health and psychological effects of cannabis use (National Drug Strategy Monograph No. 44). Canberra: Commonwealth Department of Health and Aged Care; 2001;
  65. Hall WD, Lynskey MT. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug and Alcohol Review. 2005;24(1):39–48
  66. Hall WD, MacPhee D. Cannabis use and cancer. Addiction. 2002;97(3):243–247
  67. Hall WD, Pacula RL. Cannabis use and dependence: Public health and public policy. Cambridge, UK: Cambridge University Press; 2003;
  68. Hall WD, Room R, Bondy S. Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In:  Kalant H,  Corrigal W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;p. 475–506
  69. Hall WD, Swift W. The THC content of cannabis in Australia: Evidence and implications. Australian and New Zealand Journal of Public Health. 2000;24(5):503–508
  70. Hall WD, Teesson M, Lynskey MT, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-being. Addiction. 1999;94(10):1541–1550
  71. Han C, McGue MK, Iacono WG. Lifetime tobacco, alcohol and other substance use in adolescent Minnesota twins: Univariate and multivariate behavioral genetic analyses. Addiction. 1999;94(7):981–993
  72. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005;35(3):265–275
  73. Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case–control study. Cancer Epidemiology, Biomarkers and Prevention. 2006;15(10):1829–1834
  74. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychological Bulletin. 1992;112(1):64–105
  75. Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tobacco Control. 1998;7(3):281–293
  76. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2004;330(7481):11
  77. Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB. Cannabis and schizophrenia: Model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction. 2007;102(4):597–606
  78. Hingson R, Heeren T, Mangione T, Morelock S, Mucatel M. Teenage driving after using marijuana or drinking and traffic accident involvement. Journal of Safety Research. 1982;13:33–37
  79. Hsairi M, Achour N, Zouari B, Ben Romdhane H, Achour A, Maalej M, et al. Etiologic factors in primary bronchial carcinoma in Tunisia [Facteurs etiologiques du cancer bronchique primitif en Tunisie]. Tunisie Medicale. 1993;71(5):265–268
  80. Institute of Medicine . Marijuana and medicine: Assessing the science base. Washington, DC: National Academy Press; 1999;
  81. Iversen L. The science of marijuana. 2nd ed.. Oxford: Oxford University Press; 2007;
  82. Jessor R, Jessor SL. Problem behavior and psychosocial development: A longitudinal study of youth. New York: Academic Press; 1977;
  83. Jones RT. Cardiovascular system effects of marijuana. Journal of Clinical Pharmacology. 2002;42(Suppl. 11):58S–63S
  84. Jones RT, Benowitz N, Herning RI. The 30-day trip: Clinical studies of cannabis use, tolerance and dependence. In:  Braude M,  Szara S editor. The pharmacology of marijuana. Vol. 2:New York: Academic Press; 1976;p. 627–642
  85. Kalant H. Adverse effects of cannabis on health: An update of the literature since 1996. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2004;28(5):849–863
  86. Kandel DB. Marijuana users in young adulthood. Archives of General Psychiatry. 1984;41(2):200–209
  87. Kandel DB. Issues of sequencing of adolescent drug use and other problem behaviors. Drugs and Society. 1988;3(1–2):55–76
  88. Kandel DB. Stages and pathways of drug involvement: Examining the gateway hypothesis. New York: Cambridge University Press; 2002;
  89. Kandel DB, Davies M. Progression to regular marijuana involvement: Phenomenology and risk factors for near-daily use. In:  Glantz MD editors. Vulnerability to drug abuse. Washington, DC: American Psychological Association; 1992;p. 211–253
  90. Kandel DB, Davies M, Karus D, Yamaguchi K. The consequences in young adulthood of adolescent drug involvement: An overview. Archives of General Psychiatry. 1986;43(8):746–754
  91. Kelly E, Darke S, Ross J. A review of drug use and driving: Epidemiology, impairment, risk factors and risk perceptions. Drug and Alcohol Review. 2004;23(3):319–344
  92. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51(1):8–19
  93. Kleiman MAR. Neither prohibition nor legalization: Grudging toleration in drug control policy. Daedalus. 1992;121:53–83
  94. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Experimental and Clinical Psychopharmacology. 2000;8(4):483–492
  95. Krohn MD, Lizotte AJ, Perez CM. The interrelationship between substance use and precocious transitions to adult statuses. Journal of Health and Social Behavior. 1997;38(1):87–103
  96. Lamarque S, Taghzouti K, Simon H. Chronic treatment with [Delta] 9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin: Implications for vulnerability to drug addiction. Neuropharmacology. 2001;41(1):118–129
  97. Laumon B, Gadegbeku B, Martin JL, Biecheler MB. Cannabis intoxication and fatal road crashes in France: Population based case–control study. BMJ. 2005;331(7529):1371
  98. Ledent C, Valverde O, Cossu C, Petitet F, Aubert LF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283(5400):401–404
  99. Lichtman AH, Fisher J, Martin BR. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. Pharmacology, Biochemistry and Behavior. 2001;69(1–2):181–188
  100. Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. European Journal of Pharmacology. 1998;357(2–3):139–148
  101. Lifrak PD, McKay JR, Rostain A, Alterman AI, Obrien CP. Relationship of perceived competencies, perceived social support, and gender to substance use in young adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36(7):933–940
  102. Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S. An analysis of risk factors for oral cancer in young people: A case–control study. Oral Oncology. 2004;40(3):304–313
  103. Lynskey MT. An alternative model is feasible, but the gateway hypothesis has not been invalidated: Comments on Morral et al.. Addiction. 2002;97(12):1505–1507
  104. Lynskey MT, Hall WD. The effects of adolescent cannabis use on educational attainment: A review. Addiction. 2000;96(3):433–443
  105. Lynskey MT, Heath AC, Bucholz KK, Slutske WS. Escalation of drug use in early-onset cannabis users vs. co-twin controls. Jama—Journal of the American Medical Association. 2003;289(4):427–433
  106. Lynskey MT, White V, Hill D, Letcher T, Hall WD. Prevalence of illicit drug use among youth: Results from the Australian school students’ alcohol and drugs survey. Australian and New Zealand Journal of Public Health. 1999;23(5):519–524
  107. MacCoun R, Reuter P. Drug war heresies: Learning from other vices, times and places. Cambridge, UK: Cambridge University Press; 2001;
  108. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–1588
  109. MacPhee D. Effects of marijuana on cell nuclei: A review of the literature relating to the genotoxicity of cannabis. In:  Kalant H,  Corrigall W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;p. 435–458
  110. Maldonado R. Study of cannabinoid dependence in animals. Pharmacology and Therapeutics. 2002;95:153–164
  111. Mannisto P, Kaakkola S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacological Reviews. 2006;51(4):593–628
  112. In:  Manski CF,  Pepper JV,  Petrie CV editor. Informing America's policy on illegal drugs: What we don’t know keeps hurting us. Washington, DC: National Academy Press; 2001;
  113. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences. 1999;20(7):287–294
  114. Marselos M, Karamanakos P. Mutagenicity, developmental toxicity and carcinogeneity of cannabis. Addiction Biology. 1999;4(1):5–12
  115. McDonald D, Moore R, Norberry J, Wardlaw G, Ballenden N. Legislative options for cannabis in Australia (National Drug Strategy Monograph No. 26). Canberra: Australian Government Publishing Service; 1994;
  116. McGee R, Feehan M. Cannabis use among New Zealand adolescents. New Zealand Medical Journal. 1993;106(961):345
  117. McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: A review of the literature. Addiction. 2008;103(7):1100–1109
  118. Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: A systematic review. Archives of Internal Medicine. 2006;166(13):1359–1367
  119. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103:2805–2809
  120. Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chemical Research in Toxicology. 2008;21(2):494–502
  121. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370(9584):319–328
  122. Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction. 2002;97(12):1493–1504
  123. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: The hash realities. Nature Reviews Neuroscience. 2007;8(11):885–895
  124. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369(9566):1047–1053
  125. ONDCP (2007). Study finds highest levels of THC in U.S. marijuana to date [release]. Retrieved 21 March, 2008, from http://www.whitehousedrugpolicy.gov/news/press07/042507_2.html.
  126. Osgood DW, Johnston LD, O’Malley PM, Bachman JG. The generality of deviance in late adolescence and early adulthood. American Sociological Review. 1988;53(1):81–93
  127. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology. 2005;10(2):171–180
  128. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Dependence. 2004;73(2):109–119
  129. Resnick MD, Bearman PS, Blum RW, Bauman KE, Harris KM, Jones J, et al. Protecting adolescents from harm: Findings from the National Longitudinal Study on Adolescent Health. Jama—Journal of the American Medical Association. 1997;278(10):823–832
  130. Robbe, H. W. J. (1994). Influence of marijuana on driving. Unpublished PhD. Maastricht: Institute for Human Psychopharmacology, University of Limberg.
  131. Room R, Fischer B, Hall WD, Lenton S, Reuter P. Cannabis policy: Moving beyond stalemate. The Global Cannabis Commission Report. Oxford, UK: Beckley Foundation; 2008;
  132. Rosenblatt KA, Daling JR, Chen C, Sherman KJ, Schwartz SM. Marijuana use and risk of oral squamous cell carcinoma. Cancer Research. 2004;64(11):4049–4054
  133. SAMHSA . Treatment episode data set (TEDS): Highlights-2002. National admissions to substance abuse treatment services. Rockville, MD: Office of Applied Studies, Substance and Mental Health Services Administration; 2004;
  134. Selley DA, Lichtman AH, Martin BR. Integration of molecular and behavioral approaches to evaluate cannabinoid dependence. In:  Maldonado R editors. Molecular biology of drug addiction. Totawa, NJ: Humana Press; 2003;p. 199–220
  135. Shand F, Mattick R. Clients of treatment service agencies: May 2001 Census findings (National Drug Strategy Monograph). Canberra: Commonwealth Department of Health and Ageing; 2001;
  136. Sidney S. Cardiovascular consequences of marijuana use. Journal of Clinical Pharmacology. 2002;42(Suppl. 11):64S–70S
  137. Sidney S, Quesenberry CP, Friedman GD, Tekawa IS. Marijuana use and cancer incidence (California, United States). Cancer Causes and Control. 1997;8(5):722–728
  138. Sindall C. Health policy and normative analysis: Ethics, evidence and policy. In:  Linn V,  Gibson B editor. Evidence-based health policy: Problems and possibilities.. Melbourne: Oxford University Press; 2003;p. 80–94
  139. Smart R, Fejer D. Drug use and driving among high school students. Accident Analysis and Prevention. 1976;8:33–38
  140. Smiley A. Marijuana: On road and driving simulator studies. In:  Kalant H,  Corrigall W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;
  141. Solowij N. Cannabis and cognitive functioning. Cambridge, UK: Cambridge University Press; 1998;
  142. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333–1341
  143. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence—a test of the relapse prevention model. Journal of Consulting and Clinical Psychology. 1994;62(1):92–99
  144. Swift W, Hall WD, Copeland J. Characteristics of long-term cannabis users in Sydney, Australia. European Addiction Research. 1998;4(4):190–197
  145. Swift W, Hall WD, Teesson M. Cannabis use and dependence among Australian adults: Results from the National Survey of Mental Health and Well-being. Addiction. 2001;96(5):737–748
  146. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276(5321):2048–2050
  147. Tanner J, Davies S, O’Grady B. Whatever happened to yesterday's rebels? Longitudinal effects of youth delinquency on education and employment. Social Problems. 1999;46(2):250–274
  148. Tashkin DP. Effects of cannabis on the respiratory system. In:  Kalant H,  Corrigall W,  Hall WD,  Smart R editor. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health; 1999;
  149. Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Current Opinion in Pulmonary Medicine. 2001;7:43–61
  150. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. Journal of Clinical Pharmacology. 2002;42(11):71S–81S
  151. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction. 2002;97(8):1055–1061
  152. Taylor DR, Poulton R, Moffitt T, Ramankutty P, Sears M. The respiratory effects of cannabis dependence in young adults. Addiction. 2000;95:1669–1677
  153. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Archives of Internal Medicine. 2007;167(3):221–228
  154. Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence. 1996;42(3):201–207
  155. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. Journal of Nervous and Mental Disease. 1990;178(8):473–480
  156. True WR, Heath AC, Scherrer JF, Xian H, Lin N, Eisen SA, et al. Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms. American Journal of Medical Genetics. 1999;88(4):391–397
  157. Tsou D, Patrick S, Walder J. Physical withdrawal in rats tolerant to delta-9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology. 1995;280:R13–R15
  158. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology. 2002;156(4):319–327
  159. Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. American Journal of Epidemiology. 2002;155(10):918–925
  160. Weiss C. Introduction. In:  Weiss C editors. Using social research in public policy making. Lexington, MA: Lexington Books; 1977;p. 1–22
  161. Weiss C. Ideology, interests and information: The basis of policy positions. In:  Calahan D,  Jennings B editor. Ethics, the social sciences and policy analysis. New York: Plenum Press; 1983;p. 213–245
  162. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction. 1996;91(10):1469–1478
  163. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ. 2002;325(7374):1199–1201
  164. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiology Biomarkers and Prevention. 1999;8(12):1071–1078
  165. Zimmer L, Morgan JP. Marijuana myths, marijuana facts: A review of the scientific evidence. New York: The Lindesmith Center; 1997;

PII: S0955-3959(09)00050-4

doi: 10.1016/j.drugpo.2009.02.013

International Journal of Drug Policy
Volume 20, Issue 6 , Pages 458-466 , November 2009

Article Tools